Vimarsana
Biggest News Aggregation in the World

Double Digit Royalties News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Double Digit Royalties. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Double Digit Royalties Today - Breaking & Trending Today

Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer - Vimarsana News

Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer

Published: August 16, 2023

- Precision Eligible to Receive up to $227 Million in Upfront Economics and Milestone Payments for Azer-Cel in Addition to Double-Digit Royalties on Sales- Imugene to Assume Control of Precision’s Cell Therapy Infrastructure in Pursuit of Biologics License Application for Azer-Cel in LBCL Patients who Relapse Follow...

Source: pharmiweb.com
Related Topics:
Michael AmorosoAzercabtagene ZapreleucelLeslie ChongSecurities ExchangePrecision Biosciences IncExchange CommissionImugene LimitedUpfront EconomicsMilestone PaymentsDouble Digit RoyaltiesAssume ControlCell Therapy InfrastructureBiologics License ApplicationRelapse FollowingReduced Operating Expenses Extend PrecisionExpected Cash RunwayCompany PivotsVivo GenePrecision BiosciencesChief Executive OfficerManaging DirectorPrecision BiosciencePrivate Securities Litigation Reform ActSecurities ActSecurities Exchange Act
Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories - Vimarsana News

Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories

Published: December 21, 2021

- Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe

Source: adnkronos.com
Related Topics:
United StatesUnited KingdomRichard PaulsonElcin Barker ErgunSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncMenarini Group Obtains Exclusive Rights To CommercializeEuropean CommissionDrug AdministrationPrnewswire Karyopharm Therapeutics IncExchange CommissionEuropean UnionMenarini GroupKaryopharm Selective Inhibitor Of Nuclear ExportEuropean Medicines AgencyCommittee For Medicinal Products Human UseGroup Obtains Exclusive RightsSolid Tumor Oncology IndicationsLatin AmericaFuture MilestonesPlus TieredDouble Digit RoyaltiesNet SalesSelective InhibitorNuclear Export